EODData

MEMBERSHIP REGISTER LOG IN

ASX, SPL: Starpharma Holdings Ltd.

21 May 2026
LAST:

0.6150

CHANGE:
 0.01		OPEN:
0.6050		HIGH:
0.6350		ASK:
0.0980		VOLUME:
1.46M
CHG(%):
0.82		PREV:
0.6100		LOW:
0.5900		BID:
0.0940		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
21 May 260.60500.63500.59000.61501.46M
20 May 260.59000.61000.58500.61002.19M
19 May 260.58000.59500.53500.59504.03M
18 May 260.60000.61500.54000.55003.97M
15 May 260.62500.65000.57500.62001.87M
14 May 260.73000.73250.64500.66002.06M
13 May 260.72500.75000.72000.7350583.3K
12 May 260.73500.79000.72000.74503.01M
11 May 260.72500.74000.69000.73501.53M
08 May 260.73000.73000.71500.7200775.4K

PROFILE

Name:Starpharma Holdings Ltd.
About:Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally. The company's products include VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom coating. It also involved in the development of a dendrimer-enhanced product (DEP) delivery platform, consisting of DEP SN38 for the treatment of ovarian and colorectal cancer that is in Phase II clinical trial; DEP cabazitaxel for prostate and ovarian cancer treatment that is in Phase II clinical trial; and DEP docetaxel to treat pancreatic and other cancers that is in Phase II clinical trial. In addition, the company is developing DEP HER2 radiodiagnostic and DEP HER2 ADC to treat solid tumors; DEP technology for antibody-drug conjugates; SPL7013 for vaginal gel, a treatment of bacterial vaginosis and prevention of recurrent BV, and an antiviral condom; and DEP HER2 radiodiagnostic. It has a collaboration agreement with Medicxi to develop petalion therapeutics, a novel cancer therapy using Starpharma's dendrimer technology. Starpharma Holdings Limited was incorporated in 1997 and is headquartered in Abbotsford, Australia.
Sector:Healthcare
Industry:Biotechnology
Address:4-6 Southampton Crescent, Abbotsford, VIC, Australia, 3067
Website:https://starpharma.com
ISIN:AU000000SPL0
FIGI:BBG000BW3JT0

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-16.11 
Forward P/E:-1.78 
PEG Ratio:-1.93 
Price to Sales:27.52 
Price to Book:9.80 
Profit Margin:-1.71 
Operating Margin:-1.34 
Return on Assets:-0.20 
Return on Equity:-0.42 
EPS Ratio:-0.01 
Revenue:5.85M 
Shares:419.92M 
Market Cap:258.25M 

TECHNICAL INDICATORS

MA5:0.602.8%
MA10:0.667.1%
MA20:0.6912.6%
MA50:0.594.1%
MA100:0.5023.7%
MA200:0.3860.4%
STO9:27.08
STO14:27.08
RSI14:36.62 
WPR14:-66.67
MTM14:-0.13
ROC14:-0.17 
ATR:0.05 
Week High:0.7319.1%
Week Low:0.5415.0%
Month High:0.7928.5%
Month Low:0.5460.4%
Year High:0.7928.5%
Year Low:0.08650.0%